Cargando…

Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients

BACKGROUND: Colorectal Cancer (CRC) is a major health problem around the globe. In Morocco, the disease ranks third after breast and lung cancers. This study is the first in Morocco to investigate epidemiological, clinical and therapeutic features while exhaustively describing toxic side-effects to...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoullay, Zineb, Slaoui, Meriem, Razine, Rachid, Er-Raki, Abdelouahed, Meddah, Bouchra, Cherrah, Yahia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research and Publications Office of Jimma University 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036457/
https://www.ncbi.nlm.nih.gov/pubmed/32116434
http://dx.doi.org/10.4314/ejhs.v30i1.9
_version_ 1783500222649860096
author Aoullay, Zineb
Slaoui, Meriem
Razine, Rachid
Er-Raki, Abdelouahed
Meddah, Bouchra
Cherrah, Yahia
author_facet Aoullay, Zineb
Slaoui, Meriem
Razine, Rachid
Er-Raki, Abdelouahed
Meddah, Bouchra
Cherrah, Yahia
author_sort Aoullay, Zineb
collection PubMed
description BACKGROUND: Colorectal Cancer (CRC) is a major health problem around the globe. In Morocco, the disease ranks third after breast and lung cancers. This study is the first in Morocco to investigate epidemiological, clinical and therapeutic features while exhaustively describing toxic side-effects to chemotherapy of CRC and studying the 3-years survivorship. METHODS: This is a descriptive and analytical retrospective study of about 290 patients with CRC enrolled during the period of January-December 2013. Statistical analysis was performed to correlate clinicopathological data with chemotherapy toxicity and survivorship in patients, by Chi(2) test. Overall Survival (OS) rate has been calculated by the Kaplan-Meier method and compared using Log-rank test. RESULTS: Fifty-five percent had a tumor localized in rectum, and 42,8% in colon. Mean age of these patients at diagnosis was 56,16 ± 14,6. incidence rate of adverse events (grade I to IV) was 85,6%. Diarrhea was the predominant toxicity (4.6%) occurring at a high grade (grade III–IV). The 3-years OS rate of patients with CRC was 71%. OS decreased by age, and patients with age subgroup between 40 to 59 years had a better OS than the other age subgroups (60 to 79 years and >80 years) with a p-value of 0.0001. Occurence of toxicity (all grades and types) was linked to a higher survival rates compared to the group who had no toxicity noticed (p-value of 0.001). CONCLUSION: Our study shows that patients who had a polychemotherapy had a better OS than those who had monotherapy (p-value of 0.002).
format Online
Article
Text
id pubmed-7036457
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Research and Publications Office of Jimma University
record_format MEDLINE/PubMed
spelling pubmed-70364572020-02-28 Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients Aoullay, Zineb Slaoui, Meriem Razine, Rachid Er-Raki, Abdelouahed Meddah, Bouchra Cherrah, Yahia Ethiop J Health Sci Original Article BACKGROUND: Colorectal Cancer (CRC) is a major health problem around the globe. In Morocco, the disease ranks third after breast and lung cancers. This study is the first in Morocco to investigate epidemiological, clinical and therapeutic features while exhaustively describing toxic side-effects to chemotherapy of CRC and studying the 3-years survivorship. METHODS: This is a descriptive and analytical retrospective study of about 290 patients with CRC enrolled during the period of January-December 2013. Statistical analysis was performed to correlate clinicopathological data with chemotherapy toxicity and survivorship in patients, by Chi(2) test. Overall Survival (OS) rate has been calculated by the Kaplan-Meier method and compared using Log-rank test. RESULTS: Fifty-five percent had a tumor localized in rectum, and 42,8% in colon. Mean age of these patients at diagnosis was 56,16 ± 14,6. incidence rate of adverse events (grade I to IV) was 85,6%. Diarrhea was the predominant toxicity (4.6%) occurring at a high grade (grade III–IV). The 3-years OS rate of patients with CRC was 71%. OS decreased by age, and patients with age subgroup between 40 to 59 years had a better OS than the other age subgroups (60 to 79 years and >80 years) with a p-value of 0.0001. Occurence of toxicity (all grades and types) was linked to a higher survival rates compared to the group who had no toxicity noticed (p-value of 0.001). CONCLUSION: Our study shows that patients who had a polychemotherapy had a better OS than those who had monotherapy (p-value of 0.002). Research and Publications Office of Jimma University 2020-01 /pmc/articles/PMC7036457/ /pubmed/32116434 http://dx.doi.org/10.4314/ejhs.v30i1.9 Text en © 2019 Zineb A., et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Article
Aoullay, Zineb
Slaoui, Meriem
Razine, Rachid
Er-Raki, Abdelouahed
Meddah, Bouchra
Cherrah, Yahia
Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients
title Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients
title_full Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients
title_fullStr Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients
title_full_unstemmed Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients
title_short Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients
title_sort therapeutic characteristics, chemotherapy-related toxicities and survivorship in colorectal cancer patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036457/
https://www.ncbi.nlm.nih.gov/pubmed/32116434
http://dx.doi.org/10.4314/ejhs.v30i1.9
work_keys_str_mv AT aoullayzineb therapeuticcharacteristicschemotherapyrelatedtoxicitiesandsurvivorshipincolorectalcancerpatients
AT slaouimeriem therapeuticcharacteristicschemotherapyrelatedtoxicitiesandsurvivorshipincolorectalcancerpatients
AT razinerachid therapeuticcharacteristicschemotherapyrelatedtoxicitiesandsurvivorshipincolorectalcancerpatients
AT errakiabdelouahed therapeuticcharacteristicschemotherapyrelatedtoxicitiesandsurvivorshipincolorectalcancerpatients
AT meddahbouchra therapeuticcharacteristicschemotherapyrelatedtoxicitiesandsurvivorshipincolorectalcancerpatients
AT cherrahyahia therapeuticcharacteristicschemotherapyrelatedtoxicitiesandsurvivorshipincolorectalcancerpatients